{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:21:58Z","timestamp":1787836918900,"version":"build-2784847793"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-63210-x","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T08:18:04Z","timestamp":1784535484000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative analysis of cefoperazone-sulbactam and piperacillin-tazobactam in empirical treatment of acute biliary tract infections: a multicenter, retrospective, real-world study"],"prefix":"10.1038","volume":"16","author":[{"given":"Lixing","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouye","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"issue":"1","key":"63210_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00534-006-1152-y","volume":"14","author":"Y Kimura","year":"2007","unstructured":"Kimura, Y. et al. Definitions, pathophysiology, and epidemiology of acute cholangitis and cholecystitis: Tokyo Guidelines. J. Hepatobiliary Pancreat. Surg. 14 (1), 15\u201326 (2007).","journal-title":"J. Hepatobiliary Pancreat. Surg."},{"key":"63210_CR2","unstructured":"Professional Committee of Hepatobiliary and Pancreatic Surgery of Chinese Association for Geriatric Health Care et al. National Center of Gerontology,. Expert consensus on diagnosis and treatment of acute biliary tract infection in the elderly. Chin. J. Geriatrics, 44(8):1000\u20131016. (2025)."},{"key":"63210_CR3","doi-asserted-by":"publisher","first-page":"g6241","DOI":"10.1136\/bmj.g6241","volume":"349","author":"S Warttig","year":"2014","unstructured":"Warttig, S., Ward, S., Rogers, G. & Guideline Development Group. Diagnosis and management of gallstone disease: summary of NICE guidance. BMJ 349, g6241 (2014).","journal-title":"BMJ"},{"issue":"6","key":"63210_CR4","first-page":"8","volume":"59","author":"Biliary Surgery Group, Chinese Society of Surgery, Chinese Medical Association","year":"2021","unstructured":"Biliary Surgery Group, Chinese Society of Surgery, Chinese Medical Association. Guidelines for diagnosis and treatment of acute biliary tract infections. Chin. J. Surg. 59 (6), 8 (2021).","journal-title":"Chin. J. Surg."},{"issue":"1","key":"63210_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/jhbp.509","volume":"25","author":"F Miura","year":"2018","unstructured":"Miura, F. et al. Tokyo Guidelines 2018: initial management of acute biliary infection and flowchart for acute cholangitis. J. Hepatobiliary Pancreat. Sci. 25 (1), 31\u201340 (2018).","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"issue":"1","key":"63210_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jhbp.518","volume":"25","author":"H Gomi","year":"2018","unstructured":"Gomi, H. et al. Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. J. Hepatobiliary Pancreat. Sci. 25 (1), 3\u201316 (2018).","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"issue":"7\u20138","key":"63210_CR7","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3109\/00365521.2011.560676","volume":"46","author":"E Karpel","year":"2011","unstructured":"Karpel, E. et al. Bile bacterial flora and its in vitro resistance pattern in patients with acute cholangitis resulting from choledocholithiasis. Scand. J. Gastroenterol. 46 (7\u20138), 925\u2013930 (2011).","journal-title":"Scand. J. Gastroenterol."},{"issue":"3","key":"63210_CR8","doi-asserted-by":"publisher","first-page":"dlac048","DOI":"10.1093\/jacamr\/dlac048","volume":"4","author":"YM Bezabih","year":"2022","unstructured":"Bezabih, Y. M. et al. Comparison of the global prevalence and trend of human intestinal carriage of ESBL-producing Escherichia coli between healthcare and community settings: a systematic review and meta-analysis. JAC Antimicrob. Resist. 4 (3), dlac048 (2022).","journal-title":"JAC Antimicrob. Resist."},{"issue":"1","key":"63210_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/jac\/dkaa399","volume":"76","author":"YM Bezabih","year":"2021","unstructured":"Bezabih, Y. M. et al. The global prevalence and trend of human intestinal carriage of ESBL-producing Escherichia coli in the community. J. Antimicrob. Chemother. 76 (1), 22\u201329 (2021).","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"63210_CR10","doi-asserted-by":"publisher","first-page":"dlab092","DOI":"10.1093\/jacamr\/dlab092","volume":"3","author":"M Castanheira","year":"2021","unstructured":"Castanheira, M., Simner, P. J. & Bradford, P. A. Extended-spectrum \u03b2-lactamases: an update on their characteristics, epidemiology and detection. JAC Antimicrob. Resist. 3 (3), dlab092 (2021).","journal-title":"JAC Antimicrob. Resist."},{"issue":"10","key":"63210_CR11","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1017\/ice.2017.156","volume":"38","author":"J McDanel","year":"2017","unstructured":"McDanel, J. et al. Incidence of extended-spectrum \u03b2-Lactamase (ESBL)-producing Escherichia coli and Klebsiella Infections in the United States: A systematic literature review. Infect. Control Hosp. Epidemiol. 38 (10), 1209\u20131215 (2017).","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"63210_CR12","doi-asserted-by":"publisher","first-page":"1387497","DOI":"10.3389\/fcimb.2024.1387497","volume":"14","author":"S Nasrollahian","year":"2024","unstructured":"Nasrollahian, S., Graham, J. P. & Halaji, M. A review of the mechanisms that confer antibiotic resistance in pathotypes of E. coli. Front. Cell. Infect. Microbiol. 14, 1387497 (2024).","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"3","key":"63210_CR13","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1586\/14787210.5.3.365","volume":"5","author":"A Gin","year":"2007","unstructured":"Gin, A. et al. Piperacillin-tazobactam: a beta-lactam\/beta-lactamase inhibitor combination. Expert Rev. Anti Infect. Ther. 5 (3), 365\u2013383 (2007).","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"63210_CR14","unstructured":"Gilbert, D. N. et al. The Sanford guide to antimicrobial therapy [M] 53rd edn (Antimicrobial Therapy, Inc, 2023)."},{"key":"63210_CR15","unstructured":"He, L. X. et al. National Guidelines for Antimicrobial Therapy [M] 2rd edn (People\u2019s Medical Publishing House, 2017)."},{"key":"63210_CR16","doi-asserted-by":"publisher","first-page":"104707","DOI":"10.1016\/j.meegid.2021.104707","volume":"88","author":"YH Ku","year":"2021","unstructured":"Ku, Y. H. & Yu, W. L. Cefoperazone\/sulbactam: New composites against multiresistant gram negative bacteria? Infect. Genet. Evol. 88, 104707 (2021).","journal-title":"Infect. Genet. Evol."},{"issue":"3","key":"63210_CR17","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1093\/clinids\/24.3.494","volume":"24","author":"JD Williams","year":"1997","unstructured":"Williams, J. D. beta-Lactamase inhibition and in vitro activity of sulbactam and sulbactam\/cefoperazone. Clin. Infect. Dis. 24 (3), 494\u2013497 (1997).","journal-title":"Clin. Infect. Dis."},{"issue":"10","key":"63210_CR18","first-page":"775","volume":"52","author":"J Zheng","year":"2014","unstructured":"Zheng, J. et al. Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential. Zhonghua Wai Ke Za Zhi. 52 (10), 775\u2013780 (2014).","journal-title":"Zhonghua Wai Ke Za Zhi"},{"issue":"8","key":"63210_CR19","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1089\/sur.2020.468","volume":"22","author":"SH Lan","year":"2021","unstructured":"Lan, S. H., Chao, C. M., Chang, S. P., Lu, L. C. & Lai, C. C. Clinical efficacy and safety of cefoperazone-sulbactam in treatment of intra-abdominal infections: A systematic review and meta-analysis. Surg. Infect. (Larchmt). 22 (8), 763\u2013770 (2021).","journal-title":"Surg. Infect. (Larchmt)"},{"issue":"17","key":"63210_CR20","doi-asserted-by":"publisher","first-page":"e42182","DOI":"10.1097\/MD.0000000000042182","volume":"104","author":"W Sun","year":"2025","unstructured":"Sun, W., Zhang, J., Miao, K., Ju, L. & Yuan, H. Comparison of the efficacy of cefoperazone-sulbactam and other cephalosporins in the treatment of infections: A systematic review and meta-analysis. Med. (Baltim). 104 (17), e42182 (2025).","journal-title":"Med. (Baltim)."},{"issue":"Suppl 1","key":"63210_CR21","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/0924-8579(96)00313-5","volume":"7","author":"P Mu\u00f1oz","year":"1996","unstructured":"Mu\u00f1oz, P., Garc\u00eda-Garrote, F. & Bouza, E. Broad-spectrum beta-lactam antibiotics with beta-lactamase inhibitors. Int. J. Antimicrob. Agents. 7 (Suppl 1), S9\u2013S14 (1996).","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"28","key":"63210_CR22","doi-asserted-by":"publisher","first-page":"e34284","DOI":"10.1097\/MD.0000000000034284","volume":"102","author":"CC Lai","year":"2023","unstructured":"Lai, C. C. et al. The clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of severe community-acquired pneumonia. Med. (Baltim). 102 (28), e34284 (2023).","journal-title":"Med. (Baltim)."},{"key":"63210_CR23","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.2147\/IDR.S313828","volume":"14","author":"CH Chen","year":"2021","unstructured":"Chen, C. H. et al. Clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia. Infect. Drug Resist. 14, 2251\u20132258 (2021).","journal-title":"Infect. Drug Resist."},{"issue":"29","key":"63210_CR24","doi-asserted-by":"publisher","first-page":"8694","DOI":"10.12998\/wjcc.v9.i29.8694","volume":"9","author":"XX Wang","year":"2021","unstructured":"Wang, X. X. et al. Cefoperazone sodium\/sulbactam sodium vs piperacillin sodium\/tazobactam sodium for treatment of respiratory tract infection in elderly patients. World J. Clin. Cases. 9 (29), 8694\u20138701 (2021).","journal-title":"World J. Clin. Cases"},{"issue":"1","key":"63210_CR25","doi-asserted-by":"publisher","first-page":"106491","DOI":"10.1016\/j.ijantimicag.2021.106491","volume":"59","author":"CT Huang","year":"2022","unstructured":"Huang, C. T. et al. Clinical effectiveness of cefoperazone-sulbactam vs. piperacillin-tazobactam for the treatment of pneumonia in elderly patients. Int. J. Antimicrob. Agents. 59 (1), 106491 (2022).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"63210_CR26","unstructured":"Ji, B. et al. Efficacy and safety of cefoperazone-sulbactam and piperacillin-tazobactam in treatment of complicated urinary tract infection. Chin. J. Nosocomio, (6):841\u2013846. (2024)."},{"issue":"1","key":"63210_CR27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/jhbp.515","volume":"25","author":"M Yokoe","year":"2018","unstructured":"Yokoe, M. et al. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholecystitis (with videos). J. Hepatobiliary Pancreat. Sci. 25 (1), 41\u201354 (2018).","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"issue":"1","key":"63210_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/jhbp.512","volume":"25","author":"S Kiriyama","year":"2018","unstructured":"Kiriyama, S. et al. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos). J. Hepatobiliary Pancreat. Sci. 25 (1), 17\u201330 (2018).","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"issue":"3","key":"63210_CR29","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos, A. P. et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18 (3), 268\u2013281 (2012).","journal-title":"Clin. Microbiol. Infect."},{"issue":"6","key":"63210_CR30","first-page":"532","volume":"20","author":"LJ Yang","year":"2021","unstructured":"Yang, L. J. et al. Preliminary clinical experience of combined antifungal therapy for invasive pulmonary aspergillosis in critically ill ICU patients. Chin. J. Infect. Control. 20 (6), 532\u2013536 (2021).","journal-title":"Chin. J. Infect. Control"},{"issue":"1","key":"63210_CR31","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/cc11454","volume":"17","author":"JA Kellum","year":"2013","unstructured":"Kellum, J. A., Lameire, N. & KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit. Care. 17 (1), 204 (2013).","journal-title":"Crit. Care"},{"issue":"6","key":"63210_CR32","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","volume":"70","author":"European Association for the Study of the Liver","year":"2019","unstructured":"European association for the study of the liver. EASL clinical practice guidelines: drug-induced liver injury. J. Hepatol. 70 (6), 1222\u20131261 (2019).","journal-title":"J. Hepatol."},{"issue":"8","key":"63210_CR33","first-page":"813","volume":"23","author":"Chinese Medical Association, Chinese Medical Association Publishing House, Drug-Induced Liver Disease Group, Hepatology Branch of Chinese Medical Association","year":"2024","unstructured":"Chinese medical association, chinese medical association publishing house, drug-induced liver disease group, hepatology branch of chinese medical association. chinese guideline for diagnosis and management of drug-induced liver injury in primary care (2024) [J]. Chin. J. Gen. Practitioners. 23 (8), 813\u2013830 (2024).","journal-title":"Chin. J. Gen. Practitioners"},{"key":"63210_CR34","unstructured":"China Medical Education Association. Specification for diagnosis of coagulation disorders: T\/CMEAS 019-2024[S]. (2024)."},{"key":"63210_CR35","unstructured":"Zheng, H. Pharmacokinetics of piperacillin-tazobactam sodium for injection in healthy volunteers. Chin Hosp Pharm J. 29(18):1527\u20131530 (2009)."},{"key":"63210_CR36","doi-asserted-by":"crossref","unstructured":"Craig, W. A. & Gerber, A. U. Pharmacokinetics of cefoperazone: a review. Drugs. 22 Suppl 1:35\u201345. (1981).","DOI":"10.2165\/00003495-198100221-00010"},{"issue":"33","key":"63210_CR37","first-page":"82","volume":"18","author":"ZZ Lan","year":"2025","unstructured":"Lan, Z. Z. et al. Comparison of clinical efficacy between cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of complicated urinary tract infections. Chin. J. Clin. Ration. Drug Use. 18 (33), 82\u201385 (2025).","journal-title":"Chin. J. Clin. Ration. Drug Use"},{"issue":"3","key":"63210_CR38","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1080\/1120009X.2020.1730087","volume":"32","author":"E Guclu","year":"2020","unstructured":"Guclu, E., Kaya, G., Ogutlu, A. & Karabay, O. The effect of cefoperazone sulbactam and piperacillin tazobactam on mortality in Gram-negative nosocomial infections. J. Chemother. 32 (3), 118\u2013123 (2020).","journal-title":"J. Chemother."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-63210-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-63210-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-63210-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T12:58:32Z","timestamp":1787835512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-63210-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["63210"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-63210-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"9 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"26953"}}